Tango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer TranscriptSeeking Alpha • 06/08/26
Tango Therapeutics Stock Soars 42% After 'Unprecedented' Data on Pancreatic Cancer TreatmentBarrons • 06/08/26
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic CancerGlobeNewsWire • 06/08/26
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business HighlightsGlobeNewsWire • 05/13/26
Why This CEO Is Confident His Drug Can Top 'Unprecedented' Pancreatic Cancer ResultsInvestors Business Daily • 04/30/26
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of VopimetostatGlobeNewsWire • 04/15/26
Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price SkyrocketsThe Motley Fool • 04/08/26
Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day SurgeThe Motley Fool • 03/30/26
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention24/7 Wall Street • 03/09/26
TNGX Stock Hits Record High on Inking Collaboration Deal With ERASZacks Investment Research • 03/06/26
Tango Therapeutics, Up 39% This Year, Surges Again On Another Cancer PactInvestors Business Daily • 03/05/26
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC FilingThe Motley Fool • 03/04/26
Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/14/26
Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed SuccessorGlobeNewsWire • 01/08/26
Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/17/25
Can Tango Therapeutics (TNGX) Climb 37.28% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 12/08/25